retatrutide clinical trial results 2024 2025 press release New Phase 3 data just dropped π Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Triple Agonism Based Therapies for
Description
Every cell in your body requires glucose for energy, yet too much glucose circulating in your bloodstream causes progressive damage to blood vessels, nerves, and organs over time
Foundayo: New Oral GLP-1 Option (April 2026) Oral Alternative Now Available Foundayo (orforglipron) is Eli Lilly's new oral GLP-1 medication, FDA-approved in April 2026
Harnessing snake venom phospholipases A(2) to novel approaches for overcoming antibiotic resistance
But theyre not the only ones because Eli Lilly will never be outdone by Novo Nordisk
